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Introduction
This was the second meeting held at the Jackson Labora-
tory devoted to developing improved preclinical mouse
models for breast cancer. The previous meeting was held
in October of 1997, and there has been substantial
progress made in the field in the past 2 years. This year’s
meeting was preceded by a workshop coordinated by Ger-
traud Robinson [National Institute of Diabetes and Diges-
tive and Kidney Diseases (NIDDK), National Institutes of
Health, Bethesda, Maryland, USA] designed to provide
hands-on training in the many specialized techniques that
have been developed to study the development of the
mouse mammary gland. These biologic techniques,
coupled with the use of transgenic and knockout mouse
models, provide a powerful approach to dissect the mech-
anisms by which specific genes regulate normal mammary
gland development and to identify the genetic alterations
that are involved in the initiation and progression of breast
cancer. Robert Cardiff (University of California at Davis,
California, USA) also ran a pathology tutorial that dis-
cussed the consensus terminology and recommendations
of a group of pathologists from a National Cancer Institute
sponsored workshop held in Annaopolis, Maryland, USA in
March 1999, entitled ‘Comparative Pathology of Animal
Models for Mammary Cancer’. Representative histology
images can be accessed at http://mammary.nih.gov/atlas/
histology/jaxworkshop/index.html.
The Keynote Address by Charles Daniel (University of Cal-
ifornia at Santa Cruz) provided an excellent historic per-
spective on the development of the normal mouse
mammary gland and the pioneering efforts of a number of
investigators at the Cancer Research Genetics Laboratory
at the University of California at Berkeley who helped
develop these techniques, which are so important for
studying mammary gland biology. In addition, he empha-
sized the areas that require increased study in the future.
These include studying the development of the embryonic
mammary gland, developing techniques to manipulate the
mammary stroma, incorporating information learned from
other model systems such as Caenohabditis elegans and
Drosophila into mammary gland biology, and finally investi-
gating the biology of mammary stem cells and cell senes-
cence. This year’s meeting was especially timely because
it coincided with a program just initiated by the US
National Cancer Institute: The Mouse Models of Human
Cancer Consortium.
Tumor suppressor genes
Bruce Ponder (University of Cambridge, Cambridge, UK)
discussed the usefulness of mouse models in the study of
genes that predispose humans to the development of breast
cancer. He used the example of the BRCA2 exon 11 mutant
mouse [1] to highlight the use of models in functional studies
of known genes, and discussed strategies for the identifica-
tion of modifiers of known genes in mouse models.
Barbara Weber (University of Pennsylvania, Philadelphia,
USA) presented an overview of BRCA1 and BRCA2
structure, function, and roles in various cancers, with par-
ticular emphasis on the role played in DNA repair, and dis-
cussed the development of a model in which p53 mutation
is required for cells to tolerate the loss of BRCA1. She
also described new model systems for the study of
BRCA1 function in yeast, animals, and human cell lines,
and discussed risk factors affecting penetrance of BRCA1Breast Cancer Research    Vol 2 No 1 Murphy et al
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mutation and potential modifying genes such as GST-q
and NAT2. Dan Silver (Dana-Farber Cancer Institute,
Boston, Massachusetts, USA) described reconstitution of
BRCA1 function in a BRCA1-null cell line, and also
studies detailing the subnuclear localization of the protein.
Chuxia Deng (NIDDK) described a tissue-specific muta-
tion of BRCA1 in mammary epithelium [2], leading to chro-
mosome abnormality and tumorigenesis at low frequency
after a long period. Introduction of a p53-null allele into
these mice overcomes growth defects and promotes
tumorigenesis, further indicating that BRCA1 mutation
leads to development of a genetically unstable environ-
ment in which other mutations can occur and promote
tumor development. Jean Feunteun (Institut Gustave-
Roussy, Villejuif, France) presented data implicating
BRCA1 and BRCA2 in the cellular response to oxidative
DNA damage. Transcription-coupled repair of this damage
is impaired in BRCA1- or BRCA2-deficient cells, suggest-
ing another mechanism by which BRCA1/BRCA2
pathway defects may lead to genomic instability.
Daniel Medina (Baylor College of Medicine, Houston,
Texas, USA) described studies in which p53-null
mammary epithelium was transplanted into syngeneic
wild-type mammary fat pads so that the effect of p53
absence in mammary tumorigenesis could be examined.
Intact p53-null mice develop lymphomas and die very
early. These studies showed that p53 absence is suffi-
cient to promote mammary tumorigenesis, and that this
process is enhanced by hormonal stimulation of the
animals. Furthermore, most p53-null tumors are aneuploid,
but this aneuploidy does not appear to result from aber-
rant centrosome regulation. This is inconsistent with
observations in p53-null fibroblasts, highlighting the need
to use the correct cell type in these mechanistic studies.
Angiogenesis and metastases
Judah Folkman (Children’s Hospital, Boston, Massachu-
setts, USA) discussed the use of mouse models to identify
new human angiogenesis inhibitors. Human tumors were
grown in mice and those that were found to be inhibitory
were then cultured to allow purification of the antiangio-
genic factor. In this way, a new factor was discovered [3].
aaAT-III is a 53-kDa fragment of antithrombin and is a
member of the serpin family of serine protease inhibitors.
When four other serpins involved in clotting were analyzed,
all were found to be cleaved to antiangiogenic factors.
The tumorigenicity of mouse mammary tumor virus
(MMTV) varies depending on the strain of the virus.
Tatyana Golovkina (Jackson Laboratory, Bar Harbor,
Maine, USA) showed that the C3H/HeN strain has a low
tumor incidence and is not metastatic, whereas the
C3H/HeJ strain is both tumorigenic and metastatic. The
difference between the strains was mapped to a region of
the gag gene by creating hybrid viruses. In the C3H/HeJ
metastatic tumors, increases in E-cadherin, b-catenin and
a-catenin at either the messenger RNA or protein level
were observed. This suggests that the gag region of
MMTV may be involved in deregulating cellular signaling
pathways to promote tumorigenesis and metastases.
Toshiyuki Yoneda (University of Texas Health Sciences
center, San Antonio, Texas, USA) described a mouse
model for studying bone metastases of breast cancer.
Injection of MDA-231 breast cancer cells into the left ven-
tricle of the hearts of nude mice leads to either osteolytic
or osteoblastic bone metastases. Bisphosphonate, a spe-
cific inhibitor of osteoclast bone absorption, was able to
suppress bone lysis by inducing apoptosis of the osteo-
clasts and breast cancer cells. Treatment with either a
dominant negative transforming growth factor-b2 receptor
or an antiparathyroid hormone-related protein antibody
also inhibited the growth of the bone metastases, demon-
strating that growth factors in bone are important determi-
nants of breast cancer metastases.
Carol MacLeod (University of California at San Diego) dis-
cussed the role of nitric oxide in tumor progression using
the PyV-mT mouse model. By crossing these mice with
Nos2–/– mice, tumor growth was delayed in a mixed back-
ground only. In an inbred background, the tumor burden
did not change, but the number of metastases decreased.
Cat2 is an arginine transporter that is important for pro-
duction of nitric oxide by Nos2. A cross between the PyV-
mT and Cat2–/– mice resulted in fewer and smaller lung
metastases than Cat2+/+ controls. Further work will char-
acterize the role of Cat2 in metastasis and transplantation
studies will determine whether the nitric oxide effect is
autonomous in epithelial cells.
Heparanase degrades heparan sulfate proteoglycans and
its levels are found to be elevated in the serum and urine
of cancer patients. Yael Friedmann (Hadassah-Hebrew
University Hospital, Jerusalem, Israel) described the
cloning and functional characterization of murine
heparanase. A 65-kDa precursor is cleaved to generate
the 50-kDa active form of the enzyme. Heparanase was
overexpressed in nonmetastatic T-lymphoma cells and
then injected into mice subcutaneously, resulting in a
highly metastatic phenotype.
Hormonal determinants
The role of steroid and peptide hormones in normal
mammary gland development and prevention of breast
cancer was discussed by several investigators. Paul Kelly
(INSERM, Paris, France) presented an overview of the
multiple functions of prolactin and the prolactin receptor
(PrlR) that were elucidated by studying the PrlR knockout
mouse. Mammary gland development and lactation were
severely impaired in PrlR+/– and well as PrlR–/– mice. Inter-
estingly, the heterozygote phenotype was much more3
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severe in a C57Bl/6 background than in 129SV mice,
which could be rescued after a first pregnancy. Using
mammary transplants and progesterone implants it was
determined that progesterone can re-establish side
branching in early pregnancy, but not lobuloalveolar
development. This suggests that progesterone acts on
ductal cells to stimulate side branching, and that prolactin
may act later on alveolar precursors to facilitate lobulo-
alveolar development.
Jeff Rosen (Baylor College of Medicine) discussed how
deletion of the transcription factor CCAAT/enhancer
binding protein (C/EBP)-b also resulted in a severe inhibi-
tion of lobuloalveolar development and how C/EBP-b may
regulate cell fate determination during mammary gland
development. During normal mammary gland development
the cellular distribution of the progesterone and prolactin
receptors was unexpectedly altered from a nonuniform to
a relatively uniform pattern in the ductal epithelium of
C/EBP-b–/– mice. Unexpectedly, this coincided with a
marked reduction in cell proliferation after acute stimula-
tion with estrogen and progesterone. Steroid receptor-
positive cells did not colocalize with proliferative cells,
suggesting that in the normal mammary gland steroid hor-
mones act via paracrine or possibly juxtacrine mechanisms
to stimulate cell proliferation. These results in the mouse
mimic those found in the normal human breast by Clarke
et al [4].
Malcolm Pike (University of Southern California, Los
Angeles, California, USA) discussed the mitogenic effects
of progesterone on the human breast as reflected by
breast density determined by mammography, and the
need to modify the level and route of progestin administra-
tion currently used in hormone replacement therapy to
decrease the risk of breast cancer. He also discussed a
possible prevention regimen using a GnRH agonist and a
low dose of ethinylestradiol.
Ken Korach (National Institute of Environmental Health
Sciences, Research Triangle Park, North Carolina, USA)
described the estrogen receptor (ER)-a and ER-b knock-
out mice and the crosstalk between growth factor and
steroid receptor signaling pathways. ER-b knockout mice
exhibited no significant differences in mammary gland
development, whereas the ER-a knockout mice displayed
severely inhibited ductal development. Differences were
observed in the uterus and mammary gland with respect
to the requirement for the presence of ER-a to facilitate
mitogenic effects of growth factors. Proliferative effects of
epidermal growth factor and insulin-like growth factor
were not observed in the uterus of ER-a knockout mice,
but epidermal growth factor and transforming growth
factor-a still stimulated terminal end bud proliferation in
the mammary gland. The ER-a knockout mice were
capable of responding to progesterone, resulting in
increased branching, and still developed mammary tumors
when crossed with Wnt-1 transgenic mice. Crosses of
ER-a knockout with neu transgenics displayed more dra-
matic effects on tumor latency and incidence than those
seen with the Wnt-1 crosses [5].
Ruth Keri (Case Western Reserve University School of
Medicine, Cleveland, Ohio, USA) presented a new mouse
model of ovarian hyperstimulation due to overexpression
of leutinizing hormone that resulted in ductal hypertrophy,
but infrequent tumors. Finally, Lewis Chodosh (University
of Pennsylvania, Philadelphia, USA) described the applica-
tion of gene arrays containing known genes for the poten-
tial identification of those genes involved in parity-induced
protection from breast cancer using the mouse as a
model. This powerful approach has identified a number of
gene clusters with temporal and spatial patterns of expres-
sion that make them excellent candidate biomarkers for
parity-induced protection.
New approaches for modeling breast cancer in
mice
Mouse models with immune defects have been created
mainly for acquired immune deficiency research, but these
mice can also be used as recipients for mammary gland or
breast tumor transplants, as presented by Leonard Shultz
(Jackson Laboratory, Bar Harbor, Maine, USA). By crossing
existing knockout mice, it is possible to create more human-
ized mice with lowered levels of major histocompatibility
complex class I, natural killer cells and complement, and
increase the potential level of engraftment of human tumors.
These engrafted mice can then be used to test new drugs
or immunotherapies, study mechanisms of growth and
metastasis, and identify modifiers of tumorigenesis.
A mouse model commonly used for mammary gland trans-
plants and tissue-recombination experiments is the nude
mouse (Whn–/–). Ruth Baxter (Massachusetts General
Hospital, Boston, Massachusetts, USA) presented data
characterizing the mammary gland defect that results from
a loss-of-function mutation in the Whn gene, a member of
the forkhead/winged-helix class of transcription factors.
The mammary glands of nude mice are only one-third the
size of a normal gland during pregnancy, and nude mice
are unable to lactate. Crossing nude mice with transgenic
mice expressing Whn under the control of the promoter
for the differentiation marker involucrin was able to rescue
the lactation defect.
In order to delete genes in the mouse mammary gland
specifically, two lines of mice have been created that
express Cre recombinase under the control of mammary-
specific promoters in the laboratory of Lothar Hen-
nighausen (NIDDK). Two lines of MMTV-Cre mice, one of
which is a germ-line integration, give mosaic expression in
multiple tissues. A WAP-Cre mouse line, however, givesmammary-restricted expression during late pregnancy that
continues through involution. Both the MMTV-Cre and
WAP-Cre mice were crossed with a mouse containing
loxP sites flanking exon 11 in the BRCA1 gene to create a
successful conditional mutation of BRCA1 in mammary
epithelium, as already described [2].
Eran Andrechek (McMaster University, Hamilton, Ontario,
Canada) discussed recent developments concerning the
effects of erbB2/neu oncogene on mammary gland devel-
opment and tumorigenesis. A knock-in of the neu comple-
mentary DNA into exon I of the deleted neu gene was able
to rescue embryonic lethality of the erbB2 knockout, even
though only 10% the level of wild-type neu protein was
expressed. MMTV-Cre mice were then crossed with a
floxed neo stop neuNT line to generate mice that condi-
tionally express activated neu under the transcriptional
control of the endogenous promoter. Surprisingly, ele-
vated levels of the activated neu were observed in result-
ing mammary tumors, which contained amplified copies of
the activated neu relative to the wild-type allele. Thus, this
mouse model mimics for the first time the situation in
human erbB2-positive breast tumors, in which amplifica-
tion of erbB2 has been observed.
Lewis Chodosh (University of Pennsylvania, Philadelphia,
USA) described another approach to generate a condi-
tional transgenic model in which to study the effects of the
c-myc oncogene on mammary tumorigenesis. His labora-
tory has successfully developed a tissue-restricted MMTV-
driven reverse tetracycline-controlled transactivator (rtTA)
transgenic mouse line that, when crossed with a TetO-c-
myc mouse line, was able to generate mammary tumors
when activated with doxycycline. This system was
reversible, and upon removal of doxycycline established
tumors regressed and displayed markedly decreased
rates of proliferation, but there was little change in apopto-
sis. In previous studies using the MMTV-tet system in mice
[6] the main pathology observed with the SV40 T antigen
was in the salivary gland, and not in the mammary gland.
Therefore, this MMTV-driven rtTA line developed by
Chodosh  et al should be a very useful tool for temporally
regulating the expression of genes in the mammary gland.
Experimental prevention and therapeutics
Ronald Lubet (National Cancer Institute, Bethesda, Mary-
land, USA) discussed the efficacy of tamoxifen in chemo-
prevention trials, but stressed the need for development of
agents effective against ER-negative lesions. He
described successful chemoprevention studies in the
C3(1) Tag mouse model, demonstrating that both dihydro-
epiandrosterone and 2-(difluoromethyl)-dl-ornithine are
effective chemopreventative agents. Jolene Windle
(Cancer Therapy and Research Center, San Antonio,
Texas, USA) highlighted the importance of p53 status in
response of tumors to different chemotherapeutic agents,
and discussed the relative roles of cell cycle arrest and
apoptosis in the tumor response. In the MMTV-myc mouse
model, she showed that chemotherapeutic agents that
induce cell cycle arrest are sufficient to cause tumor
response, provided that some measure of apoptosis is
naturally occurring in the tumors.
Richard Heyman (X-Ceptor Therapeutics, San Diego, Cali-
fornia, USA) showed that in a carcinogen-induced breast
cancer model, retinoid X-receptor agonists (‘rexinoids’) are
as effective as tamoxifen in the prevention of mammary
tumors and, furthermore, that rexinoids can cause regres-
sion of tamoxifen-resistant mouse tumors. This regression
appears to be the result of altered proliferation and differ-
entiation pathways. Powel Brown (Baylor College of Medi-
cine) also demonstrated the efficacy of retinoid-selective
retinoid compounds in chemoprevention studies in the
C3(1) Tag mouse model, and emphasized that reduced
toxicity can be achieved through the use of RXR-selective
retinoids.
The use of photodynamic therapy in the treatment of
mammary and salivary tumors arising in WAP-ras mice
was described by Heinrich Walt (University Hospital,
Zurich, Switzerland). Synthetic porphyrin-based photosen-
sitizers are injected into the mice, and are more selectively
taken up by tumor cells. After photosensitizer treatment,
tumors are irradiated using a laser, which results in early
apoptosis in the tumor, followed by necrosis in irradiated
areas after 96 h. This presents a potentially new approach
for tumor therapy.
Mario Colombo (Istituto Nazionale Tumori, Milan, Italy) dis-
cussed the utility of generating tumor vaccines using a
syngeneic MMTV–neuT mouse model backcrossed into
BALB/c mice in order to test for the presence of common
tumor-associated antigens. Some cross-reacting antigens
were observed that induced in vivo protection, but not a
cytotoxic T-lymphocyte response.
Emerging technologies
Two presentations covered the use of magnetic reso-
nance imaging (MRI) in visualizing a number of cellular
processes, with an emphasis on the effective delivery of a
molecular probe. James Basilion (Massachusetts General
Hospital, Boston, Massachusetts, USA) outlined the use
of MRI as a method to detect tumors or potentially monitor
gene therapy. Use of an engineered transferrin receptor
(ETR) complexed with monocrystalline iron oxide nanopar-
ticles (MION) allows for sensitive detection by MRI, with
the level of ETR expression correlating with MRI intensity.
Injection of ETR + MION into the mouse tail vein allowed
visualization of a tumor in vivo, due to preferential uptake
of ETR by tumor cells. This application should be useful in
helping tumor diagnosis by MRI. Alan Koretsky (National
Institutes of Health, Bethesda, Maryland, USA) discussed
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embryonic phenotype of knockout or transgenic mice,
measuring regional blood flow, determining the estimated
mass of organs, and track tracing in excitable and olfac-
tory cells. In addition to using MIONs in visualization, the
use of manganese as an enhancing agent was also pre-
sented. An aerosol spray of MnCl2 was used in conjunc-
tion with amyl acetate or pheremones to determine the
regions of the olfactory bulb that were responsive to these
signals.
A delivery system with great potential in the mammary
gland field described by Margaret Neville (University of
Colorado Health Sciences Center, Denver, Colorado,
USA) is that of intraductal injections. A fine glass pipet
with a tip of 60–75 mm in diameter can be easily made in
the laboratory. The uses for up-the-teat or intraductal injec-
tion include the introduction of contrast or imaging agents
for MRI, transduction of mammary epithelial cells with
adenoviral constructs, or measurement of transmembrane
permeability. Injected fluorescent probes can be directly
visualized by confocal microscopy in the living mouse,
allowing for time course studies to be performed. Intro-
duction of an adenovirus-GFP or adenovirus-LacZ con-
struct by this method has given promising results.
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